NCT06978725PHASE2, PHASE3Recruiting
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Priovant Therapeutics, Inc.
Start Date
4/9/2025
Completion Date
12/31/2029
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
1. Adults subjects
2. Cutaneous sarcoidosis with characteristic skin biopsy histology
3. A CSAMI activity score ≥ 10
4. Weight \> 40 kg to \< 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.
Exclusion Criteria
1. History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection
Interventions
DRUG
Oral Brepocitinib
DRUG
Oral Placebo
Conditions
Cutaneous Sarcoidosis
Locations
Clinical Trial Site
San Francisco, California 94115
United States
Clinical Trial Site
Durham, North Carolina 27703
United States
Clinical Trial Site
Philadelphia, Pennsylvania 19104
United States
Clinical Trial Site
Madison, Wisconsin 53715
United States